Record $122 million increase for Alzheimer's disease passed by US Congress
An unprecedented $122 million increase for Alzheimer's research, education, outreach and caregiver support stemming from the efforts of Alzheimer's Association advocates was passed swiftly by the US Congress on January 16.
The funding allocated for Alzheimer's disease includes a $100 million increase for the National Institute on Aging for Alzheimer's research, which will be added to what the National Institutes of Health (NIH) estimates will be $484 million in Alzheimer's research funding across NIH in fiscal year 2013.
A further $3.3 million has been provided to support Alzheimer's caregivers, $4 million to train health professionals on issues related to Alzheimer's disease, $10.5 million to expand the home and community based caregiver services and $4.2 million for outreach activities to raise awareness. Additionally, the National Institutes of Health's BRAIN Initiative will receive $30 million to support brain research that could impact several diseases, including Alzheimer's.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze